FDA concerns at contractor Catalent site spurred on shortages of Novo Nordisk's semaglutide — report
Just before the start of the new year, Novo Nordisk revealed its supply of obesity med Wegovy was low and that it would not be …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
